OBJECTIVE: This study was undertaken to investigate the gut microbiome in progressive multiple sclerosis (MS) and how it relates to clinical disease. METHODS: We sequenced the microbiota from healthy controls and relapsing-remitting MS (RRMS) and progressive MS patients and correlated the levels of bacteria with clinical features of disease, including Expanded Disability Status Scale (EDSS), quality of life, and brain magnetic resonance imaging lesions/atrophy. We colonized mice with MS-derived Akkermansia and induced experimental autoimmune encephalomyelitis (EAE). RESULTS: Microbiota β-diversity differed between MS patients and controls but did not differ between RRMS and progressive MS or differ based on disease-modifying therapies. Disease status had the greatest effect on the microbiome β-diversity, followed by body mass index, race, and sex. In both progressive MS and RRMS, we found increased Clostridium bolteae, Ruthenibacterium lactatiformans, and Akkermansia and decreased Blautia wexlerae, Dorea formicigenerans, and Erysipelotrichaceae CCMM. Unique to progressive MS, we found elevated Enterobacteriaceae and Clostridium g24 FCEY and decreased Blautia and Agathobaculum. Several Clostridium species were associated with higher EDSS and fatigue scores. Contrary to the view that elevated Akkermansia in MS has a detrimental role, we found that Akkermansia was linked to lower disability, suggesting a beneficial role. Consistent with this, we found that Akkermansia isolated from MS patients ameliorated EAE, which was linked to a reduction in RORγt+ and IL-17-producing γδ T cells. INTERPRETATION: Whereas some microbiota alterations are shared in relapsing and progressive MS, we identified unique bacteria associated with progressive MS and clinical measures of disease. Furthermore, elevated Akkermansia in MS may be a compensatory beneficial response in the MS microbiome. ANN NEUROL 2021;89:1195-1211.
OBJECTIVE: This study was undertaken to investigate the gut microbiome in progressive multiple sclerosis (MS) and how it relates to clinical disease. METHODS: We sequenced the microbiota from healthy controls and relapsing-remitting MS (RRMS) and progressive MS patients and correlated the levels of bacteria with clinical features of disease, including Expanded Disability Status Scale (EDSS), quality of life, and brain magnetic resonance imaging lesions/atrophy. We colonized mice with MS-derived Akkermansia and induced experimental autoimmune encephalomyelitis (EAE). RESULTS: Microbiota β-diversity differed between MS patients and controls but did not differ between RRMS and progressive MS or differ based on disease-modifying therapies. Disease status had the greatest effect on the microbiome β-diversity, followed by body mass index, race, and sex. In both progressive MS and RRMS, we found increased Clostridium bolteae, Ruthenibacterium lactatiformans, and Akkermansia and decreased Blautia wexlerae, Dorea formicigenerans, and Erysipelotrichaceae CCMM. Unique to progressive MS, we found elevated Enterobacteriaceae and Clostridium g24 FCEY and decreased Blautia and Agathobaculum. Several Clostridium species were associated with higher EDSS and fatigue scores. Contrary to the view that elevated Akkermansia in MS has a detrimental role, we found that Akkermansia was linked to lower disability, suggesting a beneficial role. Consistent with this, we found that Akkermansia isolated from MS patients ameliorated EAE, which was linked to a reduction in RORγt+ and IL-17-producing γδ T cells. INTERPRETATION: Whereas some microbiota alterations are shared in relapsing and progressive MS, we identified unique bacteria associated with progressive MS and clinical measures of disease. Furthermore, elevated Akkermansia in MS may be a compensatory beneficial response in the MS microbiome. ANN NEUROL 2021;89:1195-1211.
Authors: Luisa Möhle; Daniele Mattei; Markus M Heimesaat; Stefan Bereswill; André Fischer; Marie Alutis; Timothy French; Dolores Hambardzumyan; Polly Matzinger; Ildiko R Dunay; Susanne A Wolf Journal: Cell Rep Date: 2016-05-19 Impact factor: 9.423
Authors: Andrei N Shkoporov; Andrei V Chaplin; Victoria A Shcherbakova; Natalia E Suzina; Lyudmila I Kafarskaia; Vladimir K Bozhenko; Boris A Efimov Journal: Int J Syst Evol Microbiol Date: 2016-05-06 Impact factor: 2.747
Authors: Helen Tremlett; Douglas W Fadrosh; Ali A Faruqi; Feng Zhu; Janace Hart; Shelly Roalstad; Jennifer Graves; Susan Lynch; Emmanuelle Waubant Journal: Eur J Neurol Date: 2016-05-13 Impact factor: 6.089
Authors: David Taras; Rainer Simmering; Matthew D Collins; Paul A Lawson; Michael Blaut Journal: Int J Syst Evol Microbiol Date: 2002-03 Impact factor: 2.747
Authors: Shirong Liu; Rafael M Rezende; Thais G Moreira; Stephanie K Tankou; Laura M Cox; Meng Wu; Anya Song; Fyonn H Dhang; Zhiyun Wei; Gianluca Costamagna; Howard L Weiner Journal: Cell Host Microbe Date: 2019-11-26 Impact factor: 21.023
Authors: David H Miller; Fred D Lublin; Maria Pia Sormani; Ludwig Kappos; Özgür Yaldizli; Mark S Freedman; Bruce A C Cree; Howard L Weiner; Catherine Lubetzki; Hans-Peter Hartung; Xavier Montalban; Bernard M J Uitdehaag; David G MacManus; Tarek A Yousry; Claudia A M Gandini Wheeler-Kingshott; Bingbing Li; Norman Putzki; Martin Merschhemke; Dieter A Häring; Jerry S Wolinsky Journal: Ann Clin Transl Neurol Date: 2018-01-30 Impact factor: 4.511
Authors: Jun Chen; Nicholas Chia; Krishna R Kalari; Janet Z Yao; Martina Novotna; M Mateo Paz Soldan; David H Luckey; Eric V Marietta; Patricio R Jeraldo; Xianfeng Chen; Brian G Weinshenker; Moses Rodriguez; Orhun H Kantarci; Heidi Nelson; Joseph A Murray; Ashutosh K Mangalam Journal: Sci Rep Date: 2016-06-27 Impact factor: 4.379